University of Houston lab reports breakthrough in cancer-detecting technology

making moves

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

From Your Site Articles
CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

The UH Tech Bridge just received fresh federal funding to expand its space for innovation. Photo via UH.edu

University of Houston receives nearly $3M grant for Tech Bridge upgrades

funds granted

The University of Houston's Technology Bridge, which focuses on providing research and development space to UH-affiliated startups and entrepreneurs, has received funding to work on some upgrades.

UH received $2.875 million from the U.S. Department of Housing and Urban Development through a Community Project Funding award was included in an appropriations bill by U.S. Rep. Sylvia Garcia, who represents the region where the Tech Bridge resides.

“Congresswoman Garcia was instrumental in making this funding a reality and we are incredibly grateful for her support and for promoting the innovation ecosystem in the Houston region,” says University of Houston President Renu Khator in a news release. “The Technology Bridge is a growing community of innovators that supports the overall economic health of Houston while creating new opportunities in academia and industry."

Most of the grant will be put toward the UH Industry & International Innovation Hub, or UHI3, a rising center that will provide space for industry partner engagement, an investor and mentoring studio, startup space, training rooms, and innovation event space. The center will also have satellite office for UH’s Small Business Development Center.

The rest of the funding — $475,000 of the grant — will establish The Deck Innovation & Coworking Center, which will include eight new private offices and mail lockers for startups. According to UH, the project is expected to increase capacity by more than 20 companies.

“I am proud to have secured these funds for the University of Houston Technology Bridge. Through this investment, our community will grow stronger, and our economy will be bolstered,” says Rep. Garcia in the release. “Engagement between universities and industry is a priority as we prepare our students to be the workforce of tomorrow in a rapidly evolving world.

"The University of Houston is a world-class institution deserving of our full support, and these federal dollars are proof of that," she continues. "I am proud to represent so many UH students and faculty in Congress and will always fight to get them the resources they need to be on the cutting edge of innovation.”

Currently, the 15-building Tech Bridge and its 31,000 square feet of incubator space houses more than 20 small companies and startups that provide internship and learning opportunities for UH students, along with several federally funded research centers and institutes. The new funding will allow for the Tech Bridge to expand its impact.

“This funding will result in stronger academic and external partnerships, promote key, nationally relevant research and strengthen industry connections for our students,” says Ramanan Krishnamoorti, vice president of energy and innovation at UH. “But most importantly, it will provide an economic catalyst for startups and small businesses in the underserved communities located near the University of Houston.”

UH has launched its Tech Map, which visualizes startup and innovation activity across the city. Photo via Getty Images

University of Houston launches interactive map of the city's innovation ecosystem

introducing tech map

The greater Houston area spans 9,444 square miles — an area larger than the entire state of New Jersey — and the question was never if Houston's sprawl was going to affect interaction between startups, resources, and opportunities, but how to overcome these physical challenges with digital solutions. The latest of which has launched out of the University of Houston's Technology Bridge.

The Tech Map — an interactive, embeddable visualization that takes data about startups and other innovation players and compiles it into a map of entrepreneurial activity in the Houston area — has officially launched with hundreds of startups represented already.

"This kind of tool — it really tells you where innovation is happening, it's not just in the startup development organizations," says Lindsay Lewis, executive director of communications for the UH Division of Research. "It's amazing to see that it's happening all over the city."

The tool, which is free to embed and available to anyone, is already live on Houston Exponential's homepage and the city of Houston's Innovation Portal. It's comprised of data submitted by startup development organizations, self-submitted information, and research by the Tech Bridge's team.

To be represented on the map, click here.


Lewis stresses the importance of creating the tool in a collaborative way, which is why bringing on partners and their databases was so key. The tool isn't designed in Cougar Red or predominantly feature UH-based startups or anything. The Tech Map isn't meant to rock the boat of what any other organization is doing, rather just visually represent the goings on.

"For us, it was a balance between trying to show the story of Houston and where innovation is happening and aggregating, but what we didn't want to do was be a replacement. We wanted this to be a resource for an individual starting point," says Chris Taylor, executive director for the Tech Bridge. "The biggest challenge for most people is you really don't know where to start."

This year has been one for digital tools focused on better portraying Houston's innovation ecosystem. This summer, Houston Exponential launched the HTX TechList to virtually connect startups, mentors, investors, and other movers and shakers in Houston. The two entities are collaborative — HTX TechList's data is even involved in the Tech Map.

"There was a need for connection," Taylor says. "Since 2013 when I got here, that's always been a challenge and a hurdle. How do we connect all these different stakeholders in a way that's meaningful."

While the map is launched and ready to be used, it's only the beginning for it as it grows its data and adds new features.

"We're not done with this map — this is just the 1.0 version," Lewis says. "We're meeting to talk about next-step functionalities and where we are going to take it."

UH has been ranked among the top schools for new patents. Photo courtesy of University of Houston

University of Houston scores spot on top schools in the world for new patents

put a patent on it

A Houston school has ranked on a global list that recognizes new utility patents issued. University of Houston tied for No. 75 on the list with 39 utility patents issued in 2019.

The list is created by the National Academy of Inventors and the Intellectual Property Owners Association based on data from the U.S. Patent and Trademark Office. UH has made the list every year for the past five years.

"The rankings show that UH continues to make a major contribution to the innovation enterprise on the U.S. and global stage," says Amr Elnashai, vice president/vice chancellor for research and technology transfer at UH.

"To be in the top 100 universities worldwide for U.S. patents emphasizes that the UH research enterprise has been successfully steered towards impactful research with the potential to address societal challenges."

A utility patent, known as a patent for invention, is the most commonly referred to type of patent and regards the creation of a new or improved product, process, or machine.

Two Texas schools ranked above UH on this year's list. The University of Texas ranked at No. 3 with 276 utility patents and Texas A&M University came in a few spots ahead of UH at No. 65 with 44 utility patents issued.

UH tied with Drexel University in Philadelphia, and the University of California scored the top spot by far with 631 utility patents filed last year. All in all, the ranking finds that 7,873 U.S. utility patents were issued in 2019, which is up from 1,046 patents in 2018.

UH's Technology Bridge was revamped in 2018 to focus on cultivating innovation and new technologies as they develop from the lab and into the marketplace.

The Chancellor's Technology Bridging Fund will provide grants to UH faculty to help them bring their research and ideas into reality. Natalie Harms/InnovationMap

UH launches $2 million fund for faculty innovators to help them bring their ideas to the market

Funding the faculty

The University of Houston Technology Bridge exists to help transition university research and ideas into the marketplace, and now the UH System has gone one step further to aid in that transition process.

UH has announced a $2 million fund for faculty inventors who then could use the grants — estimated to range between $25,000 to $75,000 — to bring their invention to the commercialization stage. The fund, called the Chancellor's Technology Bridging Fund, was revealed on July 18.

"University faculty are working to solve some of the most critical problems of the day, from energy and the environment to medicine," says Renu Khator, chancellor of the UH System and president of UH, in a release. "It often requires an additional boost to get technologies from the lab to the commercial arena, and this fund is designed to help our faculty take that leap."

According to the release, UH officials plan to give out anywhere from four to 10 grants each year for the next five years.

The grants are intended to aid in the prototyping or product testing process, says Tom Campbell, executive director of the Office of Technology Transfer and Innovation in the UH Division of Research. He adds that usually that ideas in that stage of growth aren't usually granted basic research funding.

"The Technology Bridging Fund will fill a gap. It's really difficult to find funding at this early stage of development, and as a consequence, a lot of innovative concepts sit on the shelf," Campbell says in the release.

The fund directly aligns with the institution's goal of taking these UH-originated ideas, companies, and technologies and introducing them to the world, where they can be used by other companies.

"It's a way to de-risk these technologies and attract external interest," Campbell says in the release. "We want to move people and ideas closer to the market. Having access to this type of funding to do that can be extremely valuable."

Last year, UH transitioned its Energy Research Park into the Technology Bridge to better facilitate the growth for its innovators and research. The organization also works to bring in corporations that are looking to expand in Houston, and, earlier this year, two organizations set up shop in the Tech Bridge.

Earlier this year, a new ranking, new ranking, published by the National Academy of Inventors and the Intellectual Property Owners Association, puts UH at No. 88 among the world's top 100 universities for patent activity in 2018. And, according to Campbell, UH will continue this patent growth.

"As the UH research portfolio grows and the medical school starts up, we would continue to anticipate a strong IP portfolio going forward for UH," Campbell tells InnovationMap in a previous article.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings